Article
Clinical Neurology
Kate Elizabeth Therkelsen, Lauren R. Schaff, Subhiksha Nandakumar, Antonio M. P. Omuro, Lisa M. DeAngelis, Christian Grommes
Summary: This study reports the long-term survival of patients with newly diagnosed immunocompetent primary CNS lymphoma. The results showed that most patients had stable disease status after receiving medication and high-dose chemotherapy, and no disease recurrence was observed in long-term follow-up.
Article
Oncology
Zhenghua Huang, Zhen Li, Juan Wang, Ruirui Gui, Yingling Zu, Fengkuan Yu, Quande Lin, Huifang Zhao, Yanli Zhang, Baijun Fang, Yanyan Liu, Keshu Zhou, Yufu Li, Yuewen Fu, Zhihua Yao, Yongping Song, Jian Zhou
Summary: The efficacy of autologous hematopoietic stem cell transplantation (ASCT) in peripheral T-cell lymphoma (PTCL) remains controversial. This study suggests that ASCT benefits patients with complete remission (CR), while post-transplant maintenance therapy improves outcomes for patients with partial remission (PR).
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Agathe Vely, Jerome Paillassa, Christopher Nunes Gomes, Aurelien Giltat, Sophie Fouquet, Anne Lebreton, Marion Klemencie, Aline Clavert, Aline Tanguy-Schmidt, Mathilde Hunault-Berger, Corentin Orvain
Summary: This study retrospectively compared the outcomes of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) for high-risk lymphoma patients. The BEAM 200 group had less toxicity, while the survival rates were similar between the two groups.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Hua-Jay J. Cherng, Guofan Xu, Lei Feng, Raphael Steiner, Luis Fayad, Paolo Strati, Ranjit Nair, Loretta J. Nastoupil, Hun Ju Lee, Sattva S. Neelapu, Christopher R. Flowers, Maria Rodriguez, Michael Wang, Fredrick Hagemeister, Chelsea C. Pinnix, Jeremy Ramdial, Samer Srour, Yago Nieto, Katayoun Rezvani, Richard Champlin, Partow Kebriaei, Jason Westin, Homer A. Macapinlac, Elizabeth Shpall, Sairah Ahmed
Summary: PET-derived parameters can be used to predict prognosis after autologous stem cell transplantation in patients with residual disease after salvage chemotherapy for large B-cell lymphoma.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Karine Moineau-Vallee, Justine Rinfret, My Hanh Luu Hoai, Valerie St-Louis, France Berthelet, Laurent Letourneau-Guillon, Emilie Lemieux-Blanchard, Alexandre Prat, Jean-Philippe Adam
Summary: Natalizumab is used as a second-line treatment for MS and may be associated with PCNSL. In this case, the patient achieved remission after receiving PCNSL chemotherapy and ASCT.
Article
Clinical Neurology
Sophie Chatterton, Barbara Withers, Ian J. Sutton, Samuel T. Milliken, David D. F. Ma, John J. Moore, Jennifer C. Massey
Summary: After AHSCT for MS, both male and female patients may experience pregnancy, and should receive full counseling on fertility and contraception before treatment.
MULTIPLE SCLEROSIS JOURNAL
(2021)
Article
Oncology
Issa F. Khouri, Denai R. Milton, Alison M. Gulbis, Elias J. Jabbour, Loretta Nastoupil, Celina Ledesma, Paolo Anderlini, Qaiser Bashir, May Daher, Jin S. Im, Swaminathan P. Iyer, David Marin, Rohtesh S. Mehta, Amanda L. Olson, Uday R. Popat, Muzaffar Qazilbash, Neeraj Saini, Felipe Samaniego, Gabriela Rondon, L. Jeffrey Medeiros, Richard E. Champlin
Summary: In patients with relapsed follicular lymphoma, receiving alloSCT has been shown to confer better overall survival and progression-free survival compared to autoSCT.
CLINICAL CANCER RESEARCH
(2021)
Article
Veterinary Sciences
Alexandra Gareau, Alexandra Z. Ripoll, Steven E. Suter
Summary: Combining CHOP chemotherapy, autoPBHSCT, and ACT for the treatment of dogs with B-cell LSA can potentially lead to better outcomes compared to dogs treated with chemotherapy and autoPBHSCT alone, although further studies are needed to confirm the potential benefits of this aggressive treatment protocol.
FRONTIERS IN VETERINARY SCIENCE
(2021)
Article
Medicine, General & Internal
Xiaoqi Wang, Kaniel Cassady, Zhongmin Zou, Xi Zhang, Yimei Feng
Summary: The combination of PD-1 monoclonal antibody and autologous stem cell transplantation appears to be a promising regimen for treating refractory Hodgkin's lymphoma, providing a novel approach to treatment in this difficult-to-treat setting.
FRONTIERS IN MEDICINE
(2021)
Article
Hematology
A. Kuhnl, A. A. Kirkwood, C. Roddie, T. Menne, E. Tholouli, A. Bloor, C. Besley, S. Chaganti, W. Osborne, J. Norman, A. Gibb, K. Sharplin, M. Cuadrado, M. Correia de Farias, K. Cheok, L. Neill, A. L. Latif, C. Gonzalez Arias, B. Uttenthal, C. Jones, R. Johnson, A. McMillan, R. Sanderson, W. Townsend
Summary: Limited data is available on the clinical benefit of CD19 CAR T treatment in less fit large B-cell lymphoma (LBCL) patients. A real-world cohort study in the UK showed that CD19 CAR T can be safely delivered in carefully selected older patients and patients with comorbidities who are not deemed suitable for transplant, with similar response rates and survival outcomes compared to fit patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Medicine, General & Internal
Jun Du, Dandan Yu, Xinle Han, Lijun Zhu, Zoufang Huang
Summary: This study compared the efficacy and safety of allogeneic HSCT and autologous HSCT in treating refractory or relapsed peripheral T-cell lymphoma, and found that both had similar overall survival and progression-free survival outcomes, with allogeneic HSCT potentially offering specific survival benefits in certain patient populations.
Article
Oncology
Malte Roerden, Stefan Wirths, Martin Soekler, Wolfgang A. Bethge, Wichard Vogel, Juliane S. Walz
Summary: High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (Auto-HSCT) is a standard frontline treatment for fit mantle cell lymphoma (MCL) patients. However, lymphoma cell contamination of stem cell grafts may lead to poor outcomes. Analyzing residual MCL cells in autologous grafts can improve risk assessment for MCL patients undergoing Auto-HSCT.
Article
Medicine, General & Internal
Zeljka Veceric-Haler, Nika Kojc, Matjaz Sever, Samo Zver, Urban Svajger, Primoz Pozenel, Katrina Hartman, Tereza Urdih, Gregor Mlinsek, Manca Oblak, Andreja Ales Rigler, Alojz Ihan, Jadranka Buturovic Ponikvar, Philip P. Halloran, Miha Arnol
Summary: MSCs have shown promise in kidney transplantation due to their immunomodulatory and reparative properties, but their effectiveness in late post-transplant period remains unclear. This case report highlights a severe systemic complication following autologous MSC transplantation, ultimately resulting in kidney transplant failure.
FRONTIERS IN MEDICINE
(2021)
Review
Oncology
Hailing Liu, Xiao Shi, Huizi Fang, Lei Cao, Yi Miao, Xiaoli Zhao, Wei Wu, Wei Xu, Jianyong Li, Lei Fan
Summary: This study systematically reviewed the use of autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma (MCL) and found that the benefit of ASCT has been weakened in the era of rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HiDAC) treatment. Alternative first-line maintenance strategies should be explored.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Alicia Bao, Qiuhong Zhao, Ruchi Kudalkar, Jose Rodriguez, Nidhi Sharma, Naresh Bumma, Srinivas S. Devarakonda, Abdullah M. Khan, Elvira Umyarova, Ashley E. Rosko, Don Benson, Francesca Cottini
Summary: In patients with multiple myeloma undergoing autologous stem cell transplant, a gap between induction therapy and transplant allows for stem cell mobilization. However, some patients experience disease progression during this interval, which can impact response to transplant.
FRONTIERS IN ONCOLOGY
(2023)